

DAFTAR PUSTAKA

1. U.S. Cancer Statistics Working Group. CDC - about USCS - NPCR - cancer. [homepage on the Internet]. 1999-2011 [cited 2013 Apr 17]. Available from : Department of Health and Human Services, Centers for Disease Control and Prevention. Web site: <http://www.cdc.gov/cancer/npcr/uscs/about.htm>
2. Pusat Data dan Informasi Departemen Kesehatan *Profil kesehatan Indonesia 2008*. Jakarta: Departemen Kesehatan Republik Indonesia; 2009.
3. Dinas kesehatan kota Semarang *Profil kesehatan kota Semarang tahun 2009*. Semarang: DKK Semarang; 2009.
4. Sarjadi, Trihartini, Miranti IP, Insiden kanker penduduk Semarang tahun 1990-1999. *Media Medika Indonesiana* 2001; 87-92
5. National Comprehensive Cancer Network *NCCN clinical practice guidelines in oncology: Colon cancer*. 3rd ver. Washington: NCCN Inc.; 2013.
6. Pallis AG, Mouzas IA, Adjuvant chemotherapy for colon cancer. *Anticancer Research* 2006; 4809-4816
7. Johnson PW, Thomson PI, Seymour MT, Deasy NP, Thuraisingham RC, ML Slevin et al, A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas. *Br. J. Cancer* 1991; 603-605

8. Committee on The Use of Complementary and Alternative Medicine by The American Public *Complementary and alternative medicine in the United States*. Washington: The National Academies Press; 2005.
9. Tim Editorial PT. Sidomuncul. Smallcrab online. [homepage on the internet]. 2011 [cited 2012 Apr 12]. Available from : Aneka Resep Mahkota Dewa. Nutrend mahkota dewa. Web site : <http://smallcrab.com/index.php?option=com/content&task=view&id=67&Itemid=2>
10. Gangga E, Asriani H, Novita L, Analisis pendahuluan metabolit sekunder dari kalus mahkota dewa (*Phaleria macrocarpa* [Scheff.] Boerl.). Jurnal Ilmu Kefarmasian Indonesia 2007 April; 17-22
11. Harmanto N *Mahkota dewa obat pusaka para dewa: A medicine the legacy of the gods*. 6th ed. Jakarta: Agro Media Pustaka; 2003.
12. Lisdawati V. Phalerindofarma network [homepage on the internet]. 2010 [cited 2012 Apr 18]. Available from : Mahkota dewa: toksisitas, efek anti oksidan, dan efek antikanker berdasarkan uji penapisan farmakologi. Web site : <http://www.indonetwork.phalerindofarma/34716.htm>
13. Faried A, Kurnia D, Faried LS, Usman, N, Miyazaki T, Kato H, Kuwano H, Anticancer effects of gallic acid isolated from Indonesian herbal medicine *Phaleria macrocarpa* (Scheff.) Boerl on human cancer cell lines. Int J Oncol 2007; 605-613
14. Hiroko D, Teruhiko F, Shino N, Toshihiro K, Kazuo S, Analysis of cell growth inhibitory effect of catechin through MAPK in human breast cancer cell line T47D. Int J Oncol 2002; 1301-1305

15. Kusmardiyani S, Nawawi A, Rahmi K, Isolasi benzofenon dari daun mahkota dewa [*Phaleria macrocarpa* (Scheff.) Boerl.]. *Acta Pharmaceutica Indonesia* 2004; 150-152
16. Ladish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P & Darnell J *Molecular cell biology*. 6th ed. New York: Scientific American Books; 2000.
17. Bullwinkel J, Baron-Lühr B, Lüdemann A, Wohlenberg C, Gerdes J, Scholzen T, Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. *J Cell Physiol* 2006 March; 624–635
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D, Global cancer statistics 2008. *CA Cancer J Clin* 2011; 69-90
19. Parkin DM, Bray F, Ferlay J, Global cancer statistics 2002. *CA Cancer J Clin* 2011; 74-76
20. Sjamsuhidajat R, Natawijana HA & Kartowisastro H *Faktor penyebab dan resiko kanker usus besar: Simposium upaya penemuan keganasan usus besar secara dini*. Semarang: Ikabdi press; 1986.
21. Sinicrope FA, Hart J, Hsu H, Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinoma. *Clin Cancer Res* 1999; 1793-1804
22. Gordon PH & Nivatvongs S. *Principles and practice of surgery for the colon, rectum, and anus*. 3rd ed. New York: Informa Healthcare USA; 2007.
23. Center MM, Jemal A, Smith RA, Ward E, Worldwide variations in colorectal center. *CA cancer J clin* 2009; 366-378

24. Mescher AL. *Junqueira's basic histology*. 12th ed. Indiana: McGraw-Hill education; 2010.
25. Zinner MJ & Ashley SW. *Maingot's abdominal operations*. 11th ed. Boston: McGraw-Hill; 2011.
26. Brunicaardi FC, Andersen DK, Billiar TR, Dunn DL, Hunter JG, Matthews JB & et al *Schwartz's principles of surgery*. 9th ed. Houston: McGraw-Hill; 2010.
27. Rosai J *Rosai and Ackerman's surgical pathology*. 10th ed. New York: Mosby Elsevier; 2011.
28. Hamilton SR & Aaltonen LA *World Health Organization classification of tumours: Pathology and genetics of tumors of the digestive system*. Lyon: IARC Press; 2000.
29. Sobin LH & Wittekind CH *International union against cancer UICC : Classification of malignant tumors TNM*. 7th ed. Oxford: A John Wiley & Sons Inc; 2009.
30. National Comprehensive Cancer Network *NCCN clinical practice guidelines in oncology: Colon cancer*. 3rd ver. Washington: NCCN Inc.; 2013.
31. Kelompok Kerja Adenokarsinoma Kolorektal Indonesia *Pengelolaan karsinoma kolorektal : Suatu panduan klinis nasional*. Jakarta: Peraboi; 2004.
32. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC, Adjuvant therapy of colorectal cancer: Why we still don't know. *JAMA* 1988; 3571-3578

33. Wilkinson NW, Adjuvant chemotherapy for colorectal cancer: New perspective for effective treatment. *US gastroenterology review* 2007; 91-93
34. Naito Y, Saito K, Shiiba K, Ohuchi A, Saiqenji K, Naqura H et al, CD8+ T cells infiltrated within cancer cells nests as prognostic factor in human colorectal cancer. *Cancer Res* 1998; 3491-3494
35. Ali AA, McMillan DC, Matulka II, McNicol AM, McArdel CS, Tumor T-lymphocytes subset infiltration and tumor recurrence following curative resection for colorectal cancer. *Eur J Surg Oncol* 2004; 292-295
36. Cotran RS, Kumar V & Robbins SL *Robbin pathologic basis of disease*. 7th ed. Philadelphia: WB Saunders; 2007.
37. Ladish H, Baltimore D, Berk A, Zipursky SL, Matsudaira P & Darnell J *Molecular cell biology*. 6th ed. New York: Scientific American Books; 2000.
38. Vermeulen K, Van Bockstaele DR, Berneman ZN, The cell cycle : A review of regulation, deregulation and therapeutic targets in cancer. *J Cell Prolif* 2003; 131–149
39. Thomas DP & Earnshaw WC *Cell biology*. 2nd ed. Philadelphia: Saunders Elsevier; 2008.
40. Ladstein RG, Bachmann IM, Straume O, Akslen LA, Ki-67 expression is superior to mitotic count and novel proliferation marker PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. *BMC Cancer* 2010; 140-154
41. Oshima CT, Iriya K, Forones NM, Ki-67 as a prognostic marker in colorectal cancer but not in gastric cancer. *Neoplasma* 2005; 420-424

42. Hendra R, Ahmad S, Oskoueian E, Sukari A, Shukor MY, Antioxidant, anti-inflammatory and cytotoxicity of *Phaleria macrocarpa* (Boerl.) scheff fruit. *BMC Complementary and Alternative Medicine* 2011; 110-119
43. Boyd M, The NCI invitro anticancer drug discovery screen: Concept, implementation, and operation. In BA Teicher editor. *Anticancer drug development guide: preclinical screening, clinical trials and approval*. New York: Humana Press; 1975. pp.23-42
44. De Avezedo WF, Dickmann HM, Gahmen US, Worland PJ, Sausville E, Kim S, Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. *Proc Natl Acad Sci USA* 1996; 2735-2740
45. Khan M, Rasul A, Yi F, Zhong L, Ma T, Jaceosidin induces p53-dependent G2/M phase arrest in U87 glioblastoma cells. *Asian Pacific J Cancer Prev* 2011; 3235-3238
46. Fisher PM, Lane DP, Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics. *Current medicinal chemistry* 2000; 1213-1245
47. Landis SH, Murray T, Bolden S, *Cancer statistics 2000*. *CA Cancer J Clin* 2000; 1398-1424
48. Jonker D, Spithoff K, Maroun J, Gastrointestinal cancer disease site group of cancer care Ontario's program in evidence-based care, Adjuvant systemic chemotherapy for stage II and III colon cancer following complete resection: An update practice guideline. *Clin Oncol (R Coll Radiol)* 2011; 314-322

49. Andre T, O'neil BH, Meyerhardt JA, Stage III colon cancer : What works, what doesn't and why, and what's next. American Society of Clinical Oncology 2012; 223-230
50. Govindan R & Arquette MA *The Washington manual of oncology*. Washington: Lippincott Williams & Wilkins; 2002.
51. Chu E & DeVita VT *Physicians' cancer chemotherapy drug manual 2010*. Massachusetts: Jones and Bartlett Publishers; 2010.
52. De Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, et al, Leucovorin and fluorouracil without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology 2000; 2938-2947
53. Anonymous *1,2 Dimethylhydrazin. IARC Monographs Supplement. vol 7*. London: Academic Press; 1987.
54. Joseph CA, Woo YT & Argus MF *Chemical of Cancer*. London: Academic Press; 1982.
55. Nauss KM, Lockniskir M, Pavlina T, Newbere PM, Morphology and distribution of 1,2-dimethylhydrazine-induced colon tumor and their relationship to gut-associated lymphoid tissue in the rat. J Natl Cancer Inst 1984; 915-924
56. Samiasih A *Perbedaan ekspresi VEGF sel adenokarsinoma kolorektal tikus Sprague dawley dengan dan tanpa pemberian ekstrak Phyllanthus niruri*. Semarang: Magister Ilmu Biomedik Program Pasca Sarjana Universitas Diponegoro; 2010.

57. Dani V, Goel A, Vaiphei K, Dhawa K, Chemopreventive potential of zinc in experimentally induced colon carcinogenesis. *Toxicology Letters* 2007; 10-18.
58. World Health Organization *Research guidelines for evaluating the safety and efficacy of herbal medicine*. Manila: WHO Regional Office for the Western Pacific; 1993.
59. Laurence DR & Bacharach AL *Evaluation of drug activities : Pharmacometrics*. New York: Academic Press; 1964
60. Boyiadzis MM, Lebowitz PF, Frame JN & Fojo T *Hematology-oncology therapy*. New York: McGraw-Hill; 2006.
61. Tanaka T, Colorectal carcinogenesis : Review of human and experimental animal studies. *Journal of Carcinogenesis* 2009; 1-19
62. Johnson CR, Thames HD, Huang DT, Schmidt-Ullrich RK, The tumor volume and clonogen number relationship : Tumor control predictions based upon tumor volume estimates derived from computed tomography. *Int J Radiat Oncol Biol Phys* 1995; 281–287.
63. Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT et al, New guidelines to evaluate the response to treatment in solid tumors. *J Natl Cancer Inst* 2000; 205–216.
64. Balta AZ, Ozdemir Y, Sucullu I, Deric ST, Bagci M, Demirel D et al, Can horizontal diameter of colorectal tumor help predict prognosis?. *Ulusal Cer Derg* 2014; 115-119
65. Riwanto I, Budijitno S, Dharmana E, Handojo D, Prasetyo SA, Eko A et al, Effect of *Phaleria macrocarpa* supplementation on apoptosis and tumor

growth of C3h mice with breast cancer under treatment with adriamycin-cyclophosphamide. *Int Surg* 2011 Apr-Jun; 164-170

66. Budijitno S *Pengaruh ekstrak mahkota dewa terhadap skor ekspresi perforin CTL dan sel NK serta indeks apoptosis pada adenokarsinoma mamma mencit C3H*. Semarang: Magister Ilmu Biomedik Program Pasca Sarjana Universitas Diponegoro; 2006.
67. Guzinska-ustymowicz K, Pien' ES, Kemon A, MCM-2, Ki-67 and PCNA protein expressions in pT3G2. Colorectal cancer indicated lymph node involvement. *Anticancer Research* 2008; 451-458.
68. Saleh HA, Jackson H, Khatib G, Banerjee M, Correlation of Bcl-2 oncoprotein immunohistochemical expression with proliferation index and histopathologic parameters in colorectal neoplasia. *Pathol Oncol Res* 1999; 273-279.

LAMPIRAN

Lampiran 1. Perhitungan Dosis Konversi

Konversi dosis antara jenis hewan dengan manusia
(Laurence and Bacharach, 1964).⁵⁹

	Mencit 20 g	Tikus 200 g	Marmot 400 g	Kelinci 1,5 kg	Kera 4 kg	Anjing 12 kg	Manusia 70 kg
Mencit 20 g	1.0	7.0	12.25	27.8	64.1	124.3	387.9
Tikus 200 g	0.14	1.0	1.74	3.0	9.2	17.8	56.0
Marmot 400 g	0.008	0.57	1.0	2.25	5.2	10.2	31.5
Kelinci 1,5 kg	0.04	0.25	0.44	1.0	2.4	4.5	14.2
Kera 4 kg	0.016	0.11	0.19	0.42	1.0	1.9	6.1
Anjing 12 kg	0.008	0.06	0.10	0.22	0.52	1.0	3.1
Manusia 70 kg	0.0026	0.018	0.031	0.07	0.16	0.32	1.0

Dosis manusia ~berat 70 kg

Dosis tikus ~berat 200 g

Konstanta = 0.018

Konstanta hasil ekstrak *Phaleria macrocarpa* adalah 0,55%, dan hasil ekstrak diencerkan dengan aquabidest sampai tercapai konsentrasi 0,5 mg/ml. Maka dosis pemberian *Phaleria macrocarpa* pada hewan coba tikus yaitu

Dosis pemberian ekstrak *Phaleria macrocarpa*

5000 (gram) x 0,018 x 0,0055

= 0,495 mg/hr,

= 0,99 ml/hr

Lampiran 2. Hasil Pengukuran Penelitian

Kelompok	Label	Jumlah tumor	Diameter tumor (cm)	Proliferasi sel (%)
Kontrol	K 1	2	1,832	28
	K 2	4	1,414	53
	K 3	2	1,036	38
	K 4	3	1,521	29.6
	K 5	2	1,282	38
	K 6	2	1,332	36.3
Perlakuan 1	P1 1	2	1,323	16.6
	P1 2	2	1,014	31.6
	P1 3	4	1,182	41.6
	P1 4	2	1,245	25
	P1 5	3	0,903	43.3
	P1 6	4	1,144	13.3
Perlakuan 2	P2 1	2	1,156	31.6
	P2 2	3	1,340	35
	P2 3	2	1,423	50
	P2 4	3	1,314	41.6
	P2 5	3	1,481	25
	P2 6	2	1,318	30
Perlakuan 3	P3 1	1	1,258	25.6
	P3 2	2	1,220	19.3
	P3 3	4	0,827	17.6
	P3 4	3	0,973	22.6
	P3 5	2	1,019	26
	P3 6	4	1,146	24.3

Lampiran 3. Foto Penelitian





Gambar 10. Pemberian induksi *1,2 Dimethylhidrazine* secara subkutan.(kanan)

Gambar 11. Gambaran makroskopis tumor kolon. (kiri)



Gambar 12. Pengukuran massa tumor kolon


Lampiran 4. Gambaran Mikroskopis Pengecatan H&E




Gambar 13. Gambaran mikroskopis pengecatan H&E pembesaran 100x. Tampak gambaran adenokarsinoma musinosum invasif

Lampiran 5. Gambaran Mikroskopis IHC Ki-67


Gambar hasil pemeriksaan histopatologi dengan pembesaran 400 x dihitung dalam 10 lapangan pandang, proliferasi sel ditandai dengan inti sel yang berwarna coklat




Gambar 14. Gambaran mikroskopis kelompok kontrol. Tampak gambaran pewarnaan IHC Ki-67 dengan pewarnaan intensitas sedang



Gambar 15. Gambaran mikroskopis kelompok P1. Tampak gambaran pewarnaan IHC Ki-67 dengan pewarnaan intensitas kuat



Gambar 16. Gambaran mikroskopis kelompok P2. Tampak gambaran pewarnaan IHC Ki-67 dengan pewarnaan intensitas lemah



Gambar 17. Gambaran mikroskopis kelompok P3. Tampak gambaran pewarnaan IHC Ki-67 dengan pewarnaan intensitas lemah

Lampiran 6. Data Statistik

Explore Proliferasi Sel

Case Summaries

Proliferasi Sel

Kelompok	N	Mean	Std. Deviation	Median	Minimum	Maximum
K	6	37.150	8.8782	37.150	28.0	53.0
P1	6	28.567	12.5310	28.300	13.3	43.3
P2	6	35.533	8.9824	33.300	25.0	50.0
P3	6	22.567	3.4448	23.450	17.6	26.0
Total	24	30.954	10.3303	29.800	13.3	53.0

Tests of Normality

Kelompok	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Proliferasi Sel K	.295	6	.111	.876	6	.252
P1	.184	6	.200*	.921	6	.512
P2	.190	6	.200*	.955	6	.782
P3	.193	6	.200*	.903	6	.392

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

	Levene Statistic	df1	df2	Sig.
Proliferasi Sel Based on Mean	2.411	3	20	.097
Based on Median	2.180	3	20	.122
Based on Median and with adjusted df	2.180	3	15.965	.130
Based on trimmed mean	2.376	3	20	.100

Oneway

ANOVA

Proliferasi Sel

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	812.445	3	270.815	3.299	.041
Within Groups	1641.995	20	82.100		
Total	2454.440	23			

Post Hoc Tests

Multiple Comparisons

Dependent Variable: Proliferasi Sel

LSD

(I) Kelompok	(J) Kelompok	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
K	P1	8.5833	5.2313	.116	-2.329	19.496
	P2	1.6167	5.2313	.760	-9.296	12.529
	P3	14.5833*	5.2313	.011	3.671	25.496
P1	K	-8.5833	5.2313	.116	-19.496	2.329
	P2	-6.9667	5.2313	.198	-17.879	3.946
	P3	6.0000	5.2313	.265	-4.912	16.912
P2	K	-1.6167	5.2313	.760	-12.529	9.296
	P1	6.9667	5.2313	.198	-3.946	17.879
	P3	12.9667*	5.2313	.022	2.054	23.879
P3	K	-14.5833*	5.2313	.011	-25.496	-3.671
	P1	-6.0000	5.2313	.265	-16.912	4.912
	P2	-12.9667*	5.2313	.022	-23.879	-2.054

*. The mean difference is significant at the .05 level.

Explore

Ukuran Tumor Terbesar / Tikus (cm)

Case Summaries

Ukuran Tumor Terbesar / Tikus (cm)

Kelompok	N	Mean	Std. Deviation	Median	Minimum	Maximum
K	6	1.40283	.265502	1.37300	1.036	1.832
P1	6	1.13517	.153752	1.16300	.903	1.323
P2	6	1.33867	.111153	1.32900	1.156	1.481
P3	6	1.07383	.164068	1.08250	.827	1.258
Total	24	1.23762	.220276	1.25150	.827	1.832

Tests of Normality

Kelompok	Statistic	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		df	Sig.	Statistic	df	Sig.	
Ukuran Tumor Terbesar / Tikus (cm) K	.161	6	.200*	.975	6	.923	
P1	.190	6	.200*	.968	6	.878	
P2	.246	6	.200*	.944	6	.693	
P3	.170	6	.200*	.950	6	.744	

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Test of Homogeneity of Variance

		Levene Statistic	df1	df2	Sig.
Ukuran Tumor Terbesar / Tikus (cm)	Based on Mean	1.068	3	20	.385
	Based on Median	1.015	3	20	.407
	Based on Median and with adjusted df	1.015	3	11.918	.420
	Based on trimmed mean	1.061	3	20	.388

Oneway

ANOVA

Ukuran Tumor Terbesar / Tikus (cm)

	Sum of Squares	df	Mean Square	F	Sig.
Between Groups	.449	3	.150	4.487	.015
Within Groups	.667	20	.033		
Total	1.116	23			

Post Hoc Tests

Multiple Comparisons

Dependent Variable: Ukuran Tumor Terbesar / Tikus (cm)

LSD

(I) Kelompok	(J) Kelompok	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
					Lower Bound	Upper Bound
K	P1	.267667*	.105437	.020	.04773	.48761
	P2	.064167	.105437	.550	-.15577	.28411
	P3	.329000*	.105437	.005	.10906	.54894
P1	K	-.267667*	.105437	.020	-.48761	-.04773
	P2	-.203500	.105437	.068	-.42344	.01644
	P3	.061333	.105437	.567	-.15861	.28127
P2	K	-.064167	.105437	.550	-.28411	.15577
	P1	.203500	.105437	.068	-.01644	.42344
	P3	.264833*	.105437	.021	.04489	.48477
P3	K	-.329000*	.105437	.005	-.54894	-.10906
	P1	-.061333	.105437	.567	-.28127	.15861
	P2	-.264833*	.105437	.021	-.48477	-.04489

*. The mean difference is significant at the .05 level.

Explore

Case Summaries

	Ukuran Tumor Terbesar / Tikus (cm)	Proliferasi Sel
N	24	24
Mean	1.23762	30.954
Std. Deviation	.220276	10.3303
Median	1.25150	29.800
Minimum	.827	13.3
Maximum	1.832	53.0

Tests of Normality

	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
Ukuran Tumor Terbesar / Tikus (cm)	.113	24	.200*	.970	24	.663
Proliferasi Sel	.101	24	.200*	.976	24	.810

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Correlations

Correlations

		Ukuran Tumor Terbesar / Tikus (cm)	Proliferasi Sel
Ukuran Tumor Terbesar / Tikus (cm)	Pearson Correlation	1	.178
	Sig. (2-tailed)		.405
	N	24	24
Proliferasi Sel	Pearson Correlation	.178	1
	Sig. (2-tailed)	.405	
	N	24	24